Where can I find news about SOBI.ST?

The latest press releases, SEC filings, and earnings call transcripts for Swedish Orphan Biovitrum AB (SOBI.ST) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are SOBI.ST's SEC filings?

Swedish Orphan Biovitrum AB (SOBI.ST)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was SOBI.ST's last earnings call?

The most recent earnings call transcript for Swedish Orphan Biovitrum AB (SOBI.ST) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

SOBI.ST

Swedish Orphan Biovitrum AB

STO·Medical, Pharmaceuticals · Healthcare

kr 456.00kr 7.20−1.55%

Market capkr 158.36B·Market closed·Jul 23 8:08 AM UTC

Press Releases

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
/PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical
prnewswire.comJun 26, 2026 · 4:00 PM
Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
/PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical
prnewswire.comJun 26, 2026 · 3:59 PM
Sobi to present new data on pegcetacoplan at ERA 2026
/PRNewswire/ -- Sobi today announced that new data from the pegcetacoplan clinical development programme and related research in C3 glomerulopathy (C3G) and
prnewswire.comJun 1, 2026 · 4:19 AM
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
/PRNewswire/ -- Sobi (STO: SOBI) today announced positive topline results from the pivotal Phase 3 REDUCE 2 study (NCT06439602) evaluating pozdeutinurad
prnewswire.comMay 21, 2026 · 4:54 PM
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
/PRNewswire/ -- Sobi (STO: SOBI) today announced positive topline results from the pivotal Phase 3 REDUCE 2 study (NCT06439602) evaluating pozdeutinurad
prnewswire.comMay 21, 2026 · 4:51 PM
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
/PRNewswire/ -- Sobi (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza
prnewswire.comMar 30, 2026 · 2:23 AM
Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
/PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study (NCT06694701), evaluating Gamifant (emapalumab) in
prnewswire.comMar 18, 2026 · 7:02 AM
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
/PRNewswire/ -- Sobi (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its
prnewswire.comFeb 18, 2026 · 2:36 AM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for SOBI.ST and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About SOBI.ST

Where can I find news about SOBI.ST?: The latest press releases, SEC filings, and earnings call transcripts for Swedish Orphan Biovitrum AB (SOBI.ST) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are SOBI.ST's SEC filings?: Swedish Orphan Biovitrum AB (SOBI.ST)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was SOBI.ST's last earnings call?: The most recent earnings call transcript for Swedish Orphan Biovitrum AB (SOBI.ST) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Swedish Orphan Biovitrum AB

Frequently Asked Questions About SOBI.ST

Swedish Orphan Biovitrum AB

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Sobi to present new data on pegcetacoplan at ERA 2026

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

Frequently Asked Questions About SOBI.ST

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Sobi to present new data on pegcetacoplan at ERA 2026

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030